Objective:Treating peripheral nerve injury(PNI)presents a clinical challenge due to limited axon regeneration.Strychni Semen,a traditional Chinese medicine,is clinically used for numbness and hemiplegia.However,its ro...Objective:Treating peripheral nerve injury(PNI)presents a clinical challenge due to limited axon regeneration.Strychni Semen,a traditional Chinese medicine,is clinically used for numbness and hemiplegia.However,its role in promoting functional recovery after PNI and the related mechanisms have not yet been systematically studied.Methods:A mouse model of sciatic nerve crush(SNC)injury was established and the mice received drug treatment via intragastric gavage,followed by behavioral assessments(adhesive removal test,hot-plate test and Von Frey test).Transcriptomic analyses were performed to examine gene expression in the dorsal root ganglia(DRGs)from the third to the sixth lumbar vertebrae,so as to identify the significantly differentially expressed genes.Immunofluorescence staining was used to assess the expression levels of superior cervical ganglia neural-specific 10 protein(SCG10).The ultra-trace protein detection technique was used to evaluate changes in gene expression levels.Results:Strychni Semen and its active compounds(brucine and strychnine)improved functional recovery in mice following SNC injury.Transcriptomic data indicated that Strychni Semen and its active compounds initiated transcriptional reprogramming that impacted cellular morphology and extracellular matrix remodeling in DRGs after SNC,suggesting potential roles in promoting axon regeneration.Imaging data further confirmed that Strychni Semen and its active compounds facilitated axon regrowth in SNC-injured mice.By integrating protein–protein interaction predictions,ultra-trace protein detection,and molecular docking analysis,we identified myeloperoxidase as a potentially critical factor in the axon regenerative effects conferred by Strychni Semen and its active compounds.Conclusion:Strychni Semen and its active compounds enhance sensory function by promoting axonal regeneration after PNI.These findings establish a foundation for the future applications of Strychni Semen and highlight novel therapeutic strategies and drug targets for axon regeneration.展开更多
Objective: To assess the safety of individual medication of Guo's Ma Qian Decoction on the basis of effective treatment of fluorosis of bone with Guo's therapy. Methods: One hundred and fourteen cases of moder...Objective: To assess the safety of individual medication of Guo's Ma Qian Decoction on the basis of effective treatment of fluorosis of bone with Guo's therapy. Methods: One hundred and fourteen cases of moderate fluorosis of bone were randomly divided into a treatment group (n=60) and a control group (n=54) between December 2007 and August 2009 by using the block randomized method and a central random system. At the same time of basic treatment, the patients in the treatment group were orally administrated with Guo's Ma Qian Decoction. The initial dose of Ma Qian Zi (Semen Strychni) was 0.4 g and increased by 0.05 g every two days, with the doses of other drugs unchanged, until the patient had "nux vomica response". For the patients with no "nux vomica response", the dosage was continued to increase and the maximum dosage was not more than 1.2 g/day. The control group was treated with decoction placebo. The changes of strychnine and brucine contents before and after processing and after decoction of Ma Qian Zi (Semen Strychni) were determined with reversed-phase high-performance liquid chromatography, which were controlled within ranges stipulated in the Pharmacopeia; Adverse events were analyzed; Blood strychnine and brucine contents in 10 cases who had taken the drugs were determined. Results: 1) Strychnine (2.125%) and brucine (1.425%) contents before processing of Ma Qian Zi and 1.88% and 1.31% after processing all conformed with the standards of strychnine (1.2-2.2%) and brucine (no less than 0.8%) stipulated in the Pharmacopeia. When the maximum dosage of Ma Qian Zi was 1.2 g/day, strychnine in the decoction was 11.17 mg and brucine was 7.44 mg, which all conformed with the maximum limited amount (strychnine 13.32 and brucine no less than 4.8 mg) stipulated in the Pharmacopeia. 2) Eight cases had "nux vomica response" in the treatment group and one case in the control group, with a significant difference between the two groups (P<0.05). 3) Altogether 18 cases had adverse events, with an incidence rate of 15.38% (8 cases) in the treatment group and 18.52% (10 cases) in the control group, with no difference between the two groups (P>0.05); Among them, 10 cases (8.77%) with the adverse event were not related with therapeutic drugs, with an incidence rate of 6.67% (4 cases) in the treatment and 11.11% (6 cases) in the control group, with no significant difference between the two groups (P>0.05). Seven cases had suspicious relative adverse events, the risk in the treatment group was 0.658 times of the control group, with no significant difference (P>0.05), and one case had the toxic reaction of nux-vomica seed. 4) Strychnine and brucine were unable to be detected in the blood in all points of time in the 10 cases who had taken the drugs, indicating that plasma strychnine and brucine contents were lower than the minimum detectable amount (10 ng), and accumulation of strychnine and brucine were not found in blood of the patient during and after administration for 8 weeks. Conclusion: The individual medication of Ma Qian Zi (Semen Strychni) in the Guo's therapy has a better safety.展开更多
基金financially supported by the National Natural Science Foundation of China(No.82474420,No.82273903)。
文摘Objective:Treating peripheral nerve injury(PNI)presents a clinical challenge due to limited axon regeneration.Strychni Semen,a traditional Chinese medicine,is clinically used for numbness and hemiplegia.However,its role in promoting functional recovery after PNI and the related mechanisms have not yet been systematically studied.Methods:A mouse model of sciatic nerve crush(SNC)injury was established and the mice received drug treatment via intragastric gavage,followed by behavioral assessments(adhesive removal test,hot-plate test and Von Frey test).Transcriptomic analyses were performed to examine gene expression in the dorsal root ganglia(DRGs)from the third to the sixth lumbar vertebrae,so as to identify the significantly differentially expressed genes.Immunofluorescence staining was used to assess the expression levels of superior cervical ganglia neural-specific 10 protein(SCG10).The ultra-trace protein detection technique was used to evaluate changes in gene expression levels.Results:Strychni Semen and its active compounds(brucine and strychnine)improved functional recovery in mice following SNC injury.Transcriptomic data indicated that Strychni Semen and its active compounds initiated transcriptional reprogramming that impacted cellular morphology and extracellular matrix remodeling in DRGs after SNC,suggesting potential roles in promoting axon regeneration.Imaging data further confirmed that Strychni Semen and its active compounds facilitated axon regrowth in SNC-injured mice.By integrating protein–protein interaction predictions,ultra-trace protein detection,and molecular docking analysis,we identified myeloperoxidase as a potentially critical factor in the axon regenerative effects conferred by Strychni Semen and its active compounds.Conclusion:Strychni Semen and its active compounds enhance sensory function by promoting axonal regeneration after PNI.These findings establish a foundation for the future applications of Strychni Semen and highlight novel therapeutic strategies and drug targets for axon regeneration.
基金supported by a grant from "The 11th Five" National Science and Technology Support Project (2006BAI04A09-2)
文摘Objective: To assess the safety of individual medication of Guo's Ma Qian Decoction on the basis of effective treatment of fluorosis of bone with Guo's therapy. Methods: One hundred and fourteen cases of moderate fluorosis of bone were randomly divided into a treatment group (n=60) and a control group (n=54) between December 2007 and August 2009 by using the block randomized method and a central random system. At the same time of basic treatment, the patients in the treatment group were orally administrated with Guo's Ma Qian Decoction. The initial dose of Ma Qian Zi (Semen Strychni) was 0.4 g and increased by 0.05 g every two days, with the doses of other drugs unchanged, until the patient had "nux vomica response". For the patients with no "nux vomica response", the dosage was continued to increase and the maximum dosage was not more than 1.2 g/day. The control group was treated with decoction placebo. The changes of strychnine and brucine contents before and after processing and after decoction of Ma Qian Zi (Semen Strychni) were determined with reversed-phase high-performance liquid chromatography, which were controlled within ranges stipulated in the Pharmacopeia; Adverse events were analyzed; Blood strychnine and brucine contents in 10 cases who had taken the drugs were determined. Results: 1) Strychnine (2.125%) and brucine (1.425%) contents before processing of Ma Qian Zi and 1.88% and 1.31% after processing all conformed with the standards of strychnine (1.2-2.2%) and brucine (no less than 0.8%) stipulated in the Pharmacopeia. When the maximum dosage of Ma Qian Zi was 1.2 g/day, strychnine in the decoction was 11.17 mg and brucine was 7.44 mg, which all conformed with the maximum limited amount (strychnine 13.32 and brucine no less than 4.8 mg) stipulated in the Pharmacopeia. 2) Eight cases had "nux vomica response" in the treatment group and one case in the control group, with a significant difference between the two groups (P<0.05). 3) Altogether 18 cases had adverse events, with an incidence rate of 15.38% (8 cases) in the treatment group and 18.52% (10 cases) in the control group, with no difference between the two groups (P>0.05); Among them, 10 cases (8.77%) with the adverse event were not related with therapeutic drugs, with an incidence rate of 6.67% (4 cases) in the treatment and 11.11% (6 cases) in the control group, with no significant difference between the two groups (P>0.05). Seven cases had suspicious relative adverse events, the risk in the treatment group was 0.658 times of the control group, with no significant difference (P>0.05), and one case had the toxic reaction of nux-vomica seed. 4) Strychnine and brucine were unable to be detected in the blood in all points of time in the 10 cases who had taken the drugs, indicating that plasma strychnine and brucine contents were lower than the minimum detectable amount (10 ng), and accumulation of strychnine and brucine were not found in blood of the patient during and after administration for 8 weeks. Conclusion: The individual medication of Ma Qian Zi (Semen Strychni) in the Guo's therapy has a better safety.
